Answers are grounded in this paper and cite their sources.
This scientific commentary refers to ‘Clinical presentation and prognosis in MOG-antibody disease: a UK study’, by Jurynczyk et al. (doi:10.1093/brain/awx276). In this issue of Brain, Jurynczyk and co-workers describe the largest cohort of patients to date with myelin oligodendrocyte glycoprotein antibody (MOG-antibody) neuromyelitis optica spectrum disorders (NMOSD) and confirm two important points: (i) the clinical expression of MOG antibody may be included in the broadest definition of NMOSD; and (ii) the clinical profile of MOG-antibody-positive patients differs from that of patients with aquaporin-4 (AQP4)-antibody NMOSD (Juryńczyk et al., 2017a). Neuromyelitis optica (NMO) was long considered to be a subtype of multiple sclerosis. However, in 2004 a specific antibody—known initially as anti-NMO-IgG, and then later as AQP4 antibody—was found to distinguish NMO from multiple sclerosis (Lennon et al., 2004). From that point forward, NMO was considered a separate entity. The main pathogenic characteristic of NMO is the presence of AQP4 antibodies in the serum and/or CSF; this has been shown in patients and also in animal models. However, passive transfer of purified human AQP4 antibodies alone without blood–brain barrier breakdown is not sufficient to induce NMO in animal models (Jones et al., 2012). Furthermore, several experimental autoimmune encephalitis (EAE) models induced by MOG protein appear to mimic the NMO phenotype, especially in Brown Norway rats (Collongues et al., 2012). Since the discovery of AQP4 antibodies, various clinical features of AQP4-antibody-positive patients have been published, including recurrent optic neuritis and myelitis, posterior reversible encephalopathy, acute demyelinating encephalomyelitis, and brainstem and area postrema syndromes. Because of the high specificity of AQP4 antibodies, these conditions are all considered part of the expanded NMOSD. A panel of experts recently proposed revised criteria for NMO in order to offer the possibility of earlier diagnosis and treatment (Box 1). These criteria are mainly based upon the AQP4-positive status of patients, and allow a diagnosis to be made after the first clinical episode if the symptoms are highly suggestive of NMOSD: severe or bilateral optic neuritis, myelitis, area postrema/brainstem syndrome. However, a proportion of patients (20–40% depending on the cohort) with a typical phenotype of NMO are found to be negative for AQP4 antibodies (i.e. seronegative). These patients may eventually be diagnosed with NMO, but with a delay owing to the need for two relapses to have occurred in two different regions (Box 1). Multiple sclerosis research has also focused on biological markers, especially blood or cerebrospinal antibodies, for use in diagnosis and prognosis. In an attempt to translate findings from EAE models to patients, MOG antibodies and antibodies against myelin basic protein (MBP antibodies) were investigated as potential biomarkers for conversion from clinically isolated syndrome (CIS) to multiple sclerosis. However, these studies yielded mixed results even within the same laboratory, mainly owing to the limitations of early antibody detection methods (Berger et al., 2003; Lim et al., 2005). Antibodies against MOG were originally thought to be involved in classic multiple sclerosis based on results from ELISAs using linearized or denatured MOG peptides as antigen. By contrast, more recent studies using next-generation cell-based assays demonstrated a robust association of antibodies against full-length, conformationally intact human MOG protein with (mostly recurrent) optic neuritis, myelitis and brainstem encephalitis, as well as with acute disseminated encephalomyelitis (ADEM)-like presentations, rather than with classic multiple sclerosis. All of these clinical features are currently considered part of NMOSD (Wingerchuk et al., 2015). The role of immunoglobulin G serum antibodies against MOG in patients with CNS demyelination has also been revisited over the past 3 years. The clinical significance of MOG-antibodies in patients with NMOSD remains an open question: it is possible that they are expressed secondary to tissue damage as part of a bystander effect. Notably, a number of studies in adults, including the current paper by Jurynczyk et al., have detected MOG antibodies in the sera of more than 20% of NMO-seronegative patients tested by cell-based assays, but not in the sera of patients with multiple sclerosis. One issue that was not resolved with the 2015 revised criteria for NMOSD is whether the criteria for AQP4 antibodies should also apply to MOG antibodies. The phenotype of MOG-antibody-positive NMO patients is clearly consistent with NMOSD, but with several differences compared to that of AQP4-antibody patients (Reindl et al., 2017). The sex ratio (males/females) in MOG-antibody-positive NMO is ∼1, compared to 0.1 or 0.2 in AQP4-antibody patients. MOG-antibody-positive patients more frequently display isolated optic neuritis or myelitis and monophasic disease, even after long-term follow-up. Symptoms in MOG-antibody-positive patients tend to be less severe—and in severe attacks recovery and corticosteroid responses tend to be better—than in AQP4-antibody patients. Table 1 summarizes the main differences between adult patients with AQP4 and MOG antibodies. The sensitivity of MOG-antibodies is ∼10% in all NMOSD patients and 20–30% in seronegative patients. MRI in MOG-antibody-positive patients revealed more frequent brain and thoracolumbar lesions over the course of the disease when compared to AQP4-antibody-positive NMOSD patients, in whom lesions were localized to the cervicothoracic spinal cord and brainstem. The brain lesion pattern in MOG-antibody-positive patients was less specific, but there was no significant additional white matter lesion load (T2 lesion load) over time (Juryńczyk et al., 2017b). Differences between AQP4-antibody and MOG-antibody NMOSD ADEM = acute demyelinating encephalomyelitis; AQP4 = aquaporin 4; F = female; M = male; MOG = myelin oligodendrocyte glycoprotein; NMOSD = neuromyelitis optica spectrum disorder. Differences between AQP4-antibody and MOG-antibody NMOSD ADEM = acute demyelinating encephalomyelitis; AQP4 = aquaporin 4; F = female; M = male; MOG = myelin oligodendrocyte glycoprotein; NMOSD = neuromyelitis optica spectrum disorder. Diagnostic criteria (from Wingerchuk et al., 2015) Diagnostic criteria for NMOSD with AQP4-IgG At least one core clinical characteristic Positive test for AQP4-IgG using best available detection method (cell-based assay strongly recommended) Exclusion of alternative diagnoses Diagnostic criteria for NMOSD without AQP4-IgG or NMOSD with unknown AQP4-IgG status At least two core clinical characteristics occurring as a result of one or more clinical attacks and meeting all of the following requirements: (i) at least one core clinical characteristic must be optic neuritis, acute myelitis with LETM, or area postrema syndrome; (ii) dissemination in space (two or more different core clinical characteristics); and (iii) fulfilment of additional MRI requirements, as applicable Negative tests for AQP4-IgG using best available detection method, or testing unavailable Exclusion of alternative diagnoses Core clinical characteristics Optic neuritis Acute myelitis Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting Acute brainstem syndrome Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions Symptomatic cerebral syndrome with NMOSD-typical brain lesions Additional MRI requirements for NMOSD without AQP4-IgG and NMOSD with unknown AQP4-IgG status Acute optic neuritis: requires brain MRI showing (i) normal findings or only non-specific white matter lesions; OR (ii) optic nerve MRI with T2-hyperintense lesion or T1-weighted gadolinium enhancing lesion extending over >½ optic nerve length or involving optic chiasm. Acute myelitis: requires associated intramedullary MRI lesion extending over three contiguous segments (LETM) OR≥ 3 contiguous segments of focal spinal cord atrophy in patients with history compatible with acute myelitis. Area postrema syndrome: requires associated dorsal medulla/area postrema lesions. Acute brainstem syndrome: requires associated periependymal brainstem lesions. AQP4 = aquaporin-4; IgG = immunoglobulin G; LETM = longitudinally extensive transverse myelitis; NMOSD = neuromyelitis optica spectrum disorders. The main question remains the specificity of the antibodies, even with cell-based assays, given the very small number of studies of other inflammatory or autoimmune diseases. Another issue is the value of MOG-antibodies in paediatric populations (Reindl et al., 2017). MOG antibodies are found in numerous demyelinating syndromes in children and may be transient. A retest is clearly mandatory before making a definitive diagnosis of a chronic MOG-antibody disease: Pröbstel et al. (2011) found MOG antibodies to be transient in 16/25 (64%) children who were anti-MOG immunoglobulin-positive at disease onset. All of the transient patients had monophasic disease. In another recent study, Hennes et al. (2017) systematically tested 210 children with acquired demyelinating syndromes for MOG antibodies. The children were diagnosed with ADEM (n = 60), NMOSD (n = 12), CIS (n = 101) and multiple sclerosis (n = 37) after the first episode. MOG antibodies were predominantly found in ADEM (57%) and less frequently in NMOSD (25%), CIS (25%) and multiple sclerosis (8%). At 24-month follow-up, 96 children had had no further relapses. Thirty-five children developed recurrent non-multiple sclerosis episodes (63% MOG-antibody-positive and 17% AQP4-antibody-positive at onset). Seventy-nine children developed multiple sclerosis (4% MOG-antibody-positive only at onset). These findings and the possibility of transient antibody expression emphasize the importance of retesting MOG-antibody-positive patients, especially children but likely also adults, before considering a diagnosis of definite MOG-antibody NMOSD and discussing treatment options. Interestingly, several studies that used standardized cell-based assays to analyse both AQP4 antibodies and MOG antibodies in patients with an NMOSD phenotype, recurrent optic neuritis or longitudinally extensive transverse myelitis, found none of the patients to be double-positive. At present, we have little information on the best strategy for treating anti-MOG-antibody NMOSD patients (Reindl et al., 2017). In the study by Jurynczyk et al., the relapse rate was low (0.2/year) but half of the patients had significant disability after a few years of follow-up, confirming the need for a disease-modifying treatment. After the second positive test and if other diseases have been excluded, patients are treated in a similar way to classical AQP4-antibody NMOSD patients, as there are currently no data to support a distinct strategy. One may therefore suggest beginning with intravenous corticosteroids for relapses, followed by a first-line therapy such as azathioprine, mycophenolate mofetil or methotrexate as maintenance therapy if relapses are not too severe and a good recovery is achieved. The use of oral corticosteroids as a maintenance drug remains debated in both AQP4-antibody and MOG-antibody NMOSD. However, in severe cases both plasma exchange for relapses and biotherapy (e.g. rituximab, tocilizumab, mitoxantrone, cyclophosphamide) for maintenance treatment could be used to limit the consequences of the relapses (Reindl et al., 2017).
No takes yet. Share an insight, caveat, or question.
de Sèze (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: